Thinking more about therapy with convalescent plasma for COVID-19 patients

Figures & data

Table 1. Summarized information of convalescent plasma (CP) used in 34 COVID-19 patients

Reference	Sex/age (years)	Patient condition	Days from onset to CP (ml)	SARS-CoV-2 IgG before CP	SARS-CoV-2 IgG after CP
2	M/70 s	ARDS, MOF	24 (400)	+	+
	M/60 s	ARDS	14 (400)	+	+
	F/50 s	ARDS	22 (400)	+	+
	F/30 s	ARDS	21 (400)	+	+
	M/60 s	ARDS	23 (400)	+	+
3	M/46	Severe	11 (200)	1:160	1:640
	F/34	Severe	11 (200)	N/A	N/A
	M/42	Severe	19 (200)	1:320	1:640
	F/55	Severe	19 (200)	1:160	1:640
	M/57	Severe	14 (200)	1:640	1:640
	F/78	Severe	17 (200)	1:640	1:640
	M/56	Severe	16 (200)	1:320	1:640
	M/67	Severe	20 (200)	1:640	1:640
	F/49	Severe	10 (200)	1:160	1:640
	M/50	Severe	20 (200)	1:640	1:640
4	M/69	Persistent SARS-CoV-2	33, 36, 39 (each 200)	180 AU/mL	184–199 AU/mL
	F/75*	Pulmonary consolidation	33, 37 (each 200)	106 AU/mL	271–258 AU/mL
	M/56^†	Extensive lung lesions	32, 33, 36 (each 200)	72 AU/mL	143 AU/mL
	F/63^¶	With Sjögren syndrome	40 (200)	205 AU/mL	217–213 AU/mL
	F/28	Reappearance RNA +	42 (200)	162–170 AU/mL	213 AU/mL
	M/57^§	Ground glass opacities	49 (200)	217 AU/mL	N/A
5	F/69	ARDS, septic shock	23 (200); 33 (400); 34 (300)	N/A	N/A
	M/55	ARDS	16 (200)	N/A	N/A
	M/73	ARDS, MOF, septic shock	20–46 (2400, 8 times)	N/A	N/A
	F/31, pregnancy	ARDS, MOF, septic shock	24 (300)	N/A	N/A
6	M/71	ARDS	22 (500)	N/A	N/A
	F/67	Severe	7 (500)	N/A	N/A
7	F/64	Hypertension and diabetes	20 (200)	N/A	N/A
8	5 males; 32, 61^††, 62^††, 76^††, 83^††	Critical conditions (all respiratory failure, 5 ARDS, 4 secondary infection, 3 septic shock)	18–23^§§ (median 300)	N/A	N/A
	F/30^††, pregnancy	Respiratory failure	27^§§ (400); 29^§§ (200)	N/A	N/A

COVID-19, coronavirus disease 2019. SARS-CoV-2, severe acute respiratory virus coronavirus 2. ARDS, acute respiratory distress syndrome. MOF, multiple organ failure. N/A = not available.

*SARS-CoV-2 RNA negative 13 days before CP.

^†SARS-CoV-2 RNA negative 12 days before CP.

^¶SARS-CoV-2 RNA negative 16 days before CP.

^§SARS-CoV-2 RNA negative 4 days before CP.

^††Fatal.

^§§Days from positive SARS-CoV-2 RNA to CP administration.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):2601–2603. doi:10.1001/jama.2020.4783.

 Web of Science ®Google Scholar

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–96. doi:10.1073/pnas.2004168117.

 PubMed Web of Science ®Google Scholar

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. published online Apr 15 doi:10.1002/jmv.25882

 Web of Science ®Google Scholar

Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020. published online Mar 31. doi:10.1016/j.chest.2020.03.039.

 Web of Science ®Google Scholar

Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. doi:10.3346/jkms.2020.35.e149.

 PubMed Web of Science ®Google Scholar

Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, Zheng Y, Fu Q, Hu Z, Yi Y. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY). 2020;12(8):6536–42. doi:10.18632/aging.103102.

 PubMedGoogle Scholar

Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis. 2020. published online Apr 29. doi:10.1093/infdis/jiaa228.

 Web of Science ®Google Scholar